19960815
 New label on interneuron obesity drug will reflect increased risk to lungs   By Johannes, Laura, The Wall Street Journal,  Aug 23, 1996  Interneuron Pharmaceuticals Inc said it will change the label for its Redux obesity drug to show a much greater risk of a potentially fatal lung disorder.   
